Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer.

PURPOSE Previous reports have indicated that reverse transcriptase polymerase chain reaction (RT-PCR) for cytokeratin 19 (CK-19) may be useful in the management of patients with breast cancer. However, the specificity of this technique is low, principally because of a high rate of false-positive results. To improve the specificity of this assay, we developed a quantitative RT-PCR methodology that enables an estimate to be made of the number of CK-19 transcripts in blood and bone marrow samples. PATIENTS AND METHODS We examined 45 peripheral-blood samples and 30 bone marrow samples from patients with a variety of nonneoplastic conditions using nested RT-PCR for CK-19. We also examined bone marrow and peripheral-blood samples from 23 patients with primary breast cancer and peripheral-blood samples from 37 patients with metastatic breast cancer. The number of CK-19 transcripts was estimated in positive specimens by competitive PCR and normalized to the number of ABL transcripts as an internal control for the quality and quantity of cDNA. RT-PCR results were compared with the numbers of CK-19-positive cells detected by immunocytochemistry. RESULTS Analysis of samples from patients without cancer enabled us to define an upper limit for the background ratio of CK-19 to ABL transcripts (1:1,000 for blood samples and 1:1,600 for bone marrow samples). Using these figures as cut-off points, elevated CK-19: ABL ratios were detected in peripheral-blood samples of 20 of 37 (54%) patients with metastatic breast cancer and in bone marrow samples of 14 of 23 (61%) patients with primary breast cancer. Only three of 23 (13%) primary breast cancer peripheral-blood samples and none of the control samples were positive by these criteria. Only two of 23 patients (9%) with primary breast cancer showed immunocytochemically detectable cells in the blood; 10 of 23 (43%) showed immunocytochemically detectable cells in the bone marrow. Of 36 patients with metastatic breast cancer, eight (22%) showed positive events. CONCLUSION Quantitative RT-PCR for CK-19 detects a percentage of patients with breast cancer and may enable the progression or regression of the disease to be monitored.

[1]  G. Pratt,et al.  Modern molecular diagnostics and the management of haematological malignancies. , 1998, Clinical and laboratory haematology.

[2]  S. Ethier,et al.  Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Gown,et al.  Monoclonal antibodies for detection of occult carcinoma cells in bone marrow of breast cancer patients , 1989, Cancer.

[4]  J. McCall,et al.  Detection of micrometastases in colorectal cancer patients by K19 and K20 reverse-transcription polymerase chain reaction. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[5]  S. T. Traweek,et al.  Keratin gene expression in non-epithelial tissues. Detection with polymerase chain reaction. , 1993, The American journal of pathology.

[6]  K. Müller,et al.  Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Goldman,et al.  Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. , 1996, Blood.

[8]  J. Izbicki,et al.  Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. , 1994, Journal of hematotherapy.

[9]  P. Martiat,et al.  Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft‐versus‐host disease and relapse , 1993, British journal of haematology.

[10]  S. Shousha,et al.  Keratin 19 mRNA measurement to detect micrometastases in lymph nodes in breast cancer patients. , 1996, British Journal of Cancer.

[11]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[12]  R. Coombes,et al.  Detection of breast cancer micrometastases in axillary lymph nodes using the polymerase chain reaction (PCR) , 1993 .

[13]  R. Coombes,et al.  The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. , 1997, European journal of cancer.

[14]  CA-125 is not a useful marker in metastatic breast cancer. , 1992, British Journal of Cancer.

[15]  J. Goldman,et al.  Variable numbers of BCR‐ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon‐α , 1995, British journal of haematology.

[16]  S. Shousha,et al.  Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. , 1994, Cancer research.

[17]  D. Easton,et al.  Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. , 1991, European journal of cancer.

[18]  R. Cote,et al.  Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow. , 1991, Cancer research.

[19]  T. Powles,et al.  Prognostic significance of micrometastases in bone marrow in patients with primary breast cancer. , 1986, NCI monographs : a publication of the National Cancer Institute.

[20]  W. Franke,et al.  Low level expression of cytokeratins 8, 18 and 19 in vascular smooth muscle cells of human umbilical cord and in cultured cells derived therefrom, with an analysis of the chromosomal locus containing the cytokeratin 19 gene. , 1988, European journal of cell biology.

[21]  T. Powles,et al.  Physical Test for Distant Metastases in Patients with Breast Cancer , 1980, Journal of the Royal Society of Medicine.

[22]  J. Goldman,et al.  Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. , 1996, Blood.

[23]  J. Goldman,et al.  Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. , 1993 .

[24]  K. Pantel,et al.  Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.